Attached files
file | filename |
---|---|
EX-10.1 - Beyond Air, Inc. | ex10-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 18, 2020 (August 12, 2020)
Beyond Air, Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware | 001-38892 | 47-3812456 | ||
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
825 East Gate Blvd., Suite 320
Garden City, NY 11530
(Address of Principal Executive Office)
516-665-8200
(Registrant’s telephone number, including area code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
[ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
[ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b)) |
[ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Common Stock, par value $.0001 per share | XAIR | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company [X]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item 1.01. Entry into a Material Definitive Agreement.
On August 12, 2020, Beyond Air, Inc. (the “Company”) entered into a Manufacture and Supply Agreement for Medical Products (the “Agreement”) with Medisize Ireland Limited (the “Seller”) pursuant to which the Company engaged the Seller to manufacture and assemble certain components of the Company’s LungFit™ system. Prices and specifications will be set forth in statements of work.
The Agreement has an initial term of three years and shall automatically renew for additional one year terms unless otherwise terminated. The Agreement may be terminated at any time upon mutual agreement, or by either party for any reason with 6 months notice, and by either party upon the other’s breach if such breach is not cured following a 30-day notice period.
Item 9.01. Financial Statements and Exhibits.
Exhibit No. | Description | |
10.1 | Manufacture and Supply Agreement*** |
*** | Certain portions of this Exhibit were omitted by means of marking such portions with brackets (“[***]”). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
BEYOND AIR, INC. | ||
Date: August 18, 2020 | By: | /s/ Steven A. Lisi |
Steven A. Lisi | ||
Chief Executive Officer |